Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on ...

Expansion to Increase KabaFusion’s Footprint to 32 Specialty Pharmacies and 19 Ambulatory Infusion Suites Across 26 States. LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Ka ...

The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the ...

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market ...

The inducement equity award was granted to one new employee on May 19, 2025, and consisted of a non-statutory stock option to purchase up to an aggregate of 120,000 shares of common stock of the ...

Event: H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq Location: Nasdaq World Headquarters, New York, NY Fireside Chat: Tuesday, May 20, 12:30 p.m. EST Webcast: ...

Please register here to attend the conference on Wednesday, May 21 st. AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 ...

Replay: A teleconference replay of the call will be available until May 29, 2025, at (877) 344-7529 or (412) 317-0088, replay access code 7940866. Additionally, a replay of the webcast will be ...

The International Securities Identification Number for the Ordinary Shares is IE000LK2BOB4. This is an announcement under Rule 2.12 of the Irish Takeover Rules.

Title: ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation Abstract Number: 2982 Session Category: B33 – WHEEZING THROUGH THE MECHANISMS: ...

Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for ...

As of March 31, 2025, the Company had cash and cash equivalents, short-term deposits and restricted deposits in the amount of $54.8 million, compared to $62.9 million at December 31, 2024. In April ...